Search

Your search keyword '"Pathan, Ejaz"' showing total 40 results
Start Over Author "Pathan, Ejaz"
40 results on '"Pathan, Ejaz"'

3. Biomarkers of response to therapy in Ankylosing Spondylitis

Author

Pathan, Ejaz Mohammed Ishaq, Taylor, Peter, Abraham, Sonya, and Lim, Adrian Kuok

Subjects
610
Abstract

Ankylosing Spondylitis (AS) is a chronic inflammatory disorder of the spine which leads to progressive spinal fusion and deformity. With improvements in MRI, this condition is now being recognized earlier. The treatment of this condition so far is limited to physiotherapy, NSAIDs and anti-TNF therapy. The assessment of response to therapy is largely subjective using clinical outcome measures such as the Bath Ankylosing Spondylitis disease activity index (BASDAI). This thesis describes the search for an objective measure of response to therapy in AS. It does so by studying two separate patient cohorts- one receiving anti-TNF therapy and the other receiving a novel oral phosphodiesterase-4 inhibitor, apremilast, in a clinical trial setting. In addition to various clinical outcome measures and laboratory biomarkers, it also explores novel volumetric analysis of bone oedema lesions on MRI and its correlation to clinical indices. The results of this study indicate that apremilast improves clinical indices of response in AS and also modulates bone biomarkers. However, it may do so differently to anti-TNF agents with plasma sclerostin and RANKL: OPG possibly playing important roles in its mechanism of action. This study highlights the fact that different laboratory biomarkers may be modulated differently by different drugs. The novel volumetric analysis developed using Dynamika software showed promise with good correlation to established methods of scoring scans such as Berlin scoring. In particular, a novel biomarker, the product of the volume of the lesion and its intensity correlated well with changes in BASDAI in the anti-TNF cohort. However, there are a number of issues, notably inter-observer variability as well as time required to carry out the analysis, that need to be resolved. This could be done by developing automated regions of interest using this software on the basis of intensity of the lesions, hence providing an objective measure of response to therapy in AS.

Published
2013
Full Text
View/download PDF

9. Role of Metrology in Axial Spondyloarthritis: Does It Provide Unique Information in Assessing Patients and Predicting Outcome? Results From the British Society for Rheumatology Biologic Register for Ankylosing Spondylitis

Author

Biallas, Renke L., primary, Dean, Linda E., additional, Davidson, Lesley, additional, Hollick, Rosemary, additional, Pathan, Ejaz, additional, Robertson, Lindsay, additional, Jones, Gareth T., additional, Macfarlane, Gary J., additional, and Rotariu, Ovidiu, additional

Published
2022
Full Text
View/download PDF

11. Impact of biological therapy on work outcomes in patients with axial spondyloarthritis: results from the British Society for Rheumatology Biologics Register (BSRBR-AS) and meta-analysis

Author

Shim, Joanna, Jones, Gareth T, Pathan, Ejaz M I, and Macfarlane, Gary J

Subjects
Adult, Male, Biological Products, axial spondyloarthritis, Efficiency, Clinical and Epidemiological Research, Middle Aged, Presenteeism, Severity of Illness Index, United Kingdom, meta-analysis, Disability Evaluation, Treatment Outcome, work, Antirheumatic Agents, Absenteeism, Spondylarthritis, Humans, Female, biologic therapy, Registries
Abstract

Objectives To quantify, among patients with axial spondyloarthritis (axSpA), the benefit on work outcomes associated with commencing biologic therapy. Methods The British Society for Rheumatology Biologics Register in Axial Spondyloarthritis (BSRBRAS) recruited patients meeting Assessment of SpondyloArthritis International Society criteria for axSpA naïve to biological therapy across 83 centres in Great Britain. Work outcomes (measured using the Work Productivity and Activity Impairment Index) were compared between those starting biological therapy at the time of recruitment and those not. Differences between treatment groups were adjusted using propensity score matching. Results from BSRBR-AS were combined with other studies in a meta-analysis to calculate pooled estimates. Results Of the 577 participants in this analysis who were in employment, 27.9% were starting biological therapy at the time of recruitment. After propensity score adjustment, patients undergoing biological therapy, at 12-month follow-up, experienced significantly greater improvements (relative to non-biological therapy) in presenteeism (−9.4%, 95% CI −15.3% to –3.5%), overall work impairment (−13.9%, 95% CI −21.1% to –6.7%) and overall activity impairment (−19.2%, 95% CI −26.3% to –12.2%). There was no difference in absenteeism (−1.5%, 95% CI −8.0 to 4.9). Despite these improvements, impact on work was still greater in the biological treated cohort at follow-up. In the meta-analysis including 1109 subjects across observational studies and trials, treatment with biological therapy was associated with significantly greater improvements in presenteeism, work impairment and activity impairment, but there was no difference in absenteeism. Conclusions There is consistent evidence that treatment with biological therapy significantly improves work productivity and activity impairment in people with axSpA. However, there remain substantial unmet needs in relation to work.

Published
2018

12. Pyrexia of unknown origin: Kikuchi-Fujimoto disease

Author

Parappil, Ali, Rifaath, A.A., Doi, Suhail A.R., Pathan, Ejaz, and Surrun, S.K.

Subjects
Fever -- Analysis, Fever -- Case studies, Hyperthermia -- Analysis, Hyperthermia -- Case studies, Health, Health care industry
Published
2004

15. Contributors

Author

Abelson, Abby G., Abraham, Mary, Abramson, Steven B., Adachi, Jonathan D., Aggarwal, Rohit, Akira, Shizuo, Aletaha, Daniel, Ashraf Ali, Amjid, Allem, Kavitta B., Almehthel, Mohammed, Almohaya, Mohammed, Riera Alonso, Elena, Amigo, Mary-Carmen, Aringer, Martin, Arkema, Elizabeth V., Ascherman, Dana P., Atamas, Sergei P., Atkinson, Timothy J., Azeez, Maha A., Baer, Alan N., Baraliakos, Xenofon, Bardin, Thomas, Barnsley, Leslie, Barr, Andrew J., Bathon, Joan M., Belch, Jill J.F., Bellido, Teresita, Ben-Artzi, Ami, Benedetti, Fabrizio, Bennell, Kim L., Bennett, Sarah E., Berard, Roberta A., Berenbaum, Francis, Berman, Brian, Bermas, Bonnie L., Elizabeth Berry, Alice, Bertsias, George, Bhana, Suleman, Bhattacharyya, Shamik, Bilginer, Yelda, Bleasel, Jane F., Block, Joel A., Böhm, Markus, Bonelli, Michael, Boumpas, Dimitrios T., Bozec, Aline, Brasington, Richard D., Braun, Jürgen, Brouwer, Elisabeth, Brown, Jacques P., Brown, Matthew A., Brown, Matthew L., Buch, Maya H., Buckley, Christopher D., Bugbee, William D., Burmester, Gerd-Rüdiger, Burns, Jane C., Burr, David B., Buttgereit, Frank, Buxbaum, Joel N., Bykerk, Vivian P., Calabrese, Cassandra, Calabrese, Leonard H., Callen, Jeffrey P., Carr, Andrew J., Carrino, John A., Cavallo, Sabrina, Cervera, Ricard, Chang, Christopher, Chang, Joyce C., Chaon, Benjamin C., Chaudhary, Prateek, Choi, Hyon K., Choy, Ernest H.S., Christopher-Stine, Lisa, Chung, Lorinda, Ciccia, Francesco, Clauw, Daniel J., Clinch, Jacqui, Clowse, Megan E.B., Coghlan, John (Gerry), Colbert, Robert A., Conaghan, Philip G., Cooper, Cyrus, Costello, Wendy, Costenbader, Karen H., Cox, George L.D., Creamer, Paul, Cronstein, Bruce N., Cross, Raymond K., Curtis, Jeffrey R., D'Adamo, Chris, D'Agati, Vivette D., Daikh, David I., Dakin, Stephanie G., Dalbeth, Nicola, Davis, Aileen M., D'Cruz, David P., Eduardo de Barros Branco, Carlos, de Boer, Berber, De Craemer, Ann-Sophie, de Jesus, Adriana A., De Vita, Salvatore, de Wit, Maarten, Deal, Chad L., Deane, Kevin D., Dellaripa, Paul F., Dennison, Elaine, Denton, Christopher P., DiCarlo, Edward F., Distler, Oliver, Donlan, Pamela, Doyle, Tracy J., du Preez, Hannah, Dyer, George S.M., Eastell, Richard, Ehrchen, Jan, Elewaut, Dirk, Emery, Paul, Emmerling, Max R., Espinosa, Gerard, Espinoza, Luis R., Eyre, Stephen, Fanouriakis, Antonis, Farber, Joshua, Fasth, Anders, Feist, Eugen, Feldman, Candace H., Fernandez-Ruiz, Ruth, Filer, Andrew, Fiorentino, David F., Fisher, Benjamin A., Fisk, John D., Flajnik, Martin F., Forbess, Lindsy, Fox, David A., Frech, Tracy M., Frisaldi, Elisa, Gabay, Cem, Gadina, Massimo, Gandolfo, Saviana, Garelick, Daniela, Gay, Steffen, Geifman, Nophar, George, Michael D., Eric Gershwin, M., Ghadiali, Jay, Gilis, Elisabeth, Gold, Deborah T., Gold, Garry E., Goldbach-Mansky, Raphaela, Gómez-Puerta, José A., Goodman, Susan M., Gordon, Caroline, Gordon, Sharon, Gossec, Laure, Grainger, Andrew J., Grainger, Rebecca, Gravallese, Ellen M., Greenberg, Jeffrey D., Guglielmi, Luiza Guilherme, Gül, Ahmet, Gullapalli, Rao P., Guma, Monica, Gupta, Sarthak, Han, Shuhong, Hanly, John G., Hanson, Eric P., Haraoui, Boulos, Harley, John B., Haroun, Tayseer G., Hashkes, Philip J., Hasni, Sarfaraz A., Bassim Hassan, Andrew, Haupt, Lukas, Hausmann, Jonathan S., Hawker, Gillian A., Heiberg, Turid, Helfgott, Simon M., Hinman, Rana S., Hoffmann-Vold, Anna-Maria, Holroyd, Christopher R., Holt, Cathy, Horomanski, Audra, Huizinga, Thomas W.J., Humby, Frances, Elaine Husni, M., Hwang, Jonathan, Hyrich, Kimme, Inman, Robert D., Inoue, Dai, Isaac, Zacharia, Isaacs, John D., Isenberg, David, Iversen, Maura D., Jabs, Douglas A., James, Judith A., Jandali, Bochra, Kassim Javaid, M., Javier, Rose-Marie, Jefferis, Roy, Jeffries, Matlock A., Johnson, Sindhu R., Johnstone, Brian, Helena Jonsson, Anna, Joyce, Andrew A., Jung, Michelle, Kado, Ruba, Kaisho, Tsuneyasu, Kamal, Natasha, Kane, David, Kaplan, Mariana J., Karr, Timothy L., Kassimos, Dimitrios G., Kastner, Daniel L., Katz, Jeffrey N., Kawano, Mitsuhiro, Kay, Jonathan, Keating, Richard M., Kelly, Jennifer A., Kendler, David, Keyser, Randall E., Khamashta, Munther A., Khanna, Dinesh, Khokhar, Kiran, Kiefer, David, King, Lauren K., Kloppenburg, Margreet, Kolasinski, Sharon L., Kolstad, Kathleen D., Kottyan, Leah C., Byers Kraus, Virginia, Kronberger, Leo R.W., Kroopnick, Jeffrey M., Kvien, Tore K., LaBaer, Joshua, Lafyatis, Robert, Lakkis, Jay I., Landewé, Robert B.M., Langford, Carol A., Laster, Marciana L., Latourte, Augustin, Lau, Arthur N., Laurynenka, Viktoryia, Lavin, Robert A., Laxer, Ronald M., Li, Suzanne C., Liao, Katherine P., Lieberman, Scott M., Liew, Jean W., Littlejohn, Geoffrey O., Liu, Eva S., Lo, Lawrence, Lories, Rik J., Luger, Thomas A., Lundberg, Ingrid E., Luqmani, Raashid A., Machado, Pedro M., Machold, Klaus P., Ronald MacKenzie, C., Major, Tanya J., Malfait, Anne-Marie, Malley, Tamir, Manasson, Julia, March, Lyn M., Olivé Marqués, Alejandro, Márquez, Javier, Martin, Paul, Martínez-Lavín, Manuel, Matteson, Eric L., Mayes, Maureen D., McAlindon, Timothy, McCarthy, Edward F., McCarthy, Geraldine M., McDermott, Michael F., McDonnell, Patrick J., McGonagle, Dennis, Simon Meara, Alexa, Mehta, Jay J., Melville, Andrew R., Merola, Joseph F., Micheletti, Robert G., Michou, Laëtitia, Middleton, Rob, Midha, Disha, Mikdashi, Jamal A., Miller, Frederick W., Minden, Kirsten, Miner, Jonathan J., Minhas, Deeba, Helene Moe, Rikke, Möller, Ingrid, Mopuru, Renuka, Mortaji, Parisa, Mueller, Alisa A., Myasoedova, Elena, Namur, Gauthier, Naredo, Esperanza, Navarro-Compán, Victoria, Neerinckx, Barbara, Nelson, Amanda E., Nerviani, Alessandra, Nicolson, Philippa J.A., Nordal, Ellen B., Nöth, Ulrich, Ntatsaki, Eleana, Obenhuber, Tilman, Oddis, Chester V., Ogdie-Beatty, Alexis R., Omar, Ahmed, Ombrello, Michael J., Omisade, Antonina, Onel, Karen B., Ong, Voon H., Orcel, Philippe, Orozco, Gisela, Orr, Carl, O'Shea, John J., Ospelt, Caroline, Østensen, Monika, Özen, Seza, Park, Elizabeth, Parker, Matthew J.S., Pathan, Ejaz, Patrono, Carlo, Perez-Chada, Lourdes M., Pijnenburg, Luc, Pillinger, Michael H., Pineda, Carlos, Pipitone, Nicolò, Pitzalis, Costantino, Poddubnyy, Denis, Pope, Janet E., Postolova, Anna, Price, Andrew J., Pryor, Katherine P., Quartuccio, Luca, Rackwitz, Lars, Radner, Helga, Rajendran, Aardra, Ramiro, Sofia, Raychaudhuri, Soumya, Redmond, Anthony C., Reeves, Westley H., Remmers, Elaine F., Requena, Luis, Reynolds, Gary, Reynolds, John A., Ribbens, Clio, Richards, Bethan, Richardson, Bruce, Richette, Pascal, Ritchlin, Christopher T., Ritter, Susan Y., Robinson, Philip C., Robinson, William H., Rogers, Valerie J., Romain, Paul L., Rosas, Ivan O., Rosenthal, Ann K., Rubin, Elka, Rudwaleit, Martin, Rutgers, Bram A., Rygg, Marite, Saag, Kenneth G., Salmon, Jane E., Salusky, Isidro B., Salvarani, Carlo, Sandell, Linda J., Sandhu, Vaneet K., Sandovici, Maria, Sand-Svartrud, Anne-Lene, Scanzello, Carla R., Schaible, Hans-Georg, Scher, Jose U., Schett, Georg, Schiffenbauer, Adam I., Schiller, Alan L., Schlesinger, Naomi, Schreiber, Benjamin E., Schwartz, Daniella M., Shaibani, Aziz, Sharma, Leena, Shmerling, Robert H., Siaton, Bernadette C., Siegel, Richard M., Sieghart, Daniela, Silverman, Stuart L., Simard, Julia F., Simmons, Barry P., Simms, Robert W., Singer, Nora G., Sirotich, Emily, Smith, Judith A., Smith, Stacy E., Smolen, Josef S., Solomon, Daniel H., Sparks, Jeffrey A., Stack, John, Stanley, David, Steen, Virginia D., Steere, Allen C., Stegeman, Coen A., Steiner, Günter, Steinert, Andre F., Stojan, George, Strand, Vibeke, Sufka, Paul, Sullivan, James K., Szulc, Pawel, Tang, Chen, Tang, Shiyu, Taylor, Peter C., Terkeltaub, Robert, Thomas, Afton R., Thorne, Jennifer E., Topping, Louise M., Toprover, Michael, Torralba, Karina, Touma, Zahi, Tremoulet, Adriana H., Trouw, Leendert, Tuan, Rocky S., Uçkay, Ilker, Umehara, Hisanori, van der Geest, Kornelis S.M., van der Heijde, Désirée, van Gaalen, Floris A., Van Mechelen, Margot, van Vollenhoven, Ronald F., Vandevelde, Claire Y.J., Varga, John, Vassilopoulos, Dimitrios, Veale, Douglas J., Verstappen, Gwenny M., Viatte, Sebastien, Vincent, Tonia L., Vital, Edward M., von Loga, Isabell S., Wahezi, Dawn M., Wallace, Daniel J., Wallace, Zachary S., Warburton, Gary, Watad, Abdulla, Watts, Richard A., Weinblatt, Michael E., Weir, Matthew R., Weisman, Michael H., Weiss, Pamela F., Branford White, Harriet, White, Kenneth E., Wilkinson, David J., Williams, David E., Williams, Richard, Wilson, Hannah, Winthrop, Kevin L., Witt, Claudia M., Witzmann, Gerhard, Wong, John B., Woolf, Anthony D., Paul Wordsworth, B., Xu, Huji, Yazdany, Jinoos, Young, David A., Young, Stephen P., Md Yusof, Md Yuzaiful, and Zhuang, Haoyang

Published
2023
Full Text
View/download PDF

22. Influence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis: results from a UK national register

Author

Macfarlane, Gary J, MacDonald, Ross I R, Pathan, Ejaz, Siebert, Stefan, Gaffney, Karl, Choy, Ernest, Packham, Jon, Martin, Kathryn R, Haywood, Kirstie, Sengupta, Raj, Atzeni, Fabiola, and Jones, Gareth T

Subjects
Adult, Male, disease register, response, Fibromyalgia, United Nations, Tumor Necrosis Factor-alpha, axial spondyloarthritis, Clinical Science, Middle Aged, Severity of Illness Index, Treatment Outcome, Antirheumatic Agents, Spondylarthritis, cohort study, outcome, Humans, epidemiology, Female, biologic therapy, Registries, co-morbidity, disease activity, Axial spondyloarthritis, Biologic therapy, Co-morbidity, Cohort study, Disease activity, Disease register, Epidemiology, Outcome, Response, Aged
Abstract

Objective:\ud \ud To quantify the extent to which co-morbid FM is associated with higher disease activity, worse quality of life (QoL) and poorer response to TNF inhibitors (TNFis) in patients with axial SpA.\ud Methods:\ud \ud A prospective study recruiting across 83 centres in the UK. Clinical information and patient-reported measures were available, including 2011 criteria for FM. Multivariable linear regression was used to model the effect of meeting the FM criteria on disease activity, QoL and response to TNFis.\ud Results:\ud \ud A total of 1757 participants were eligible for analyses, of whom 22.1% met criteria for FM. Those with co-morbid FM criteria had higher disease activity [BASDAI average difference FM+ − FM− 1.04 (95% CI 0.75, 1.33)] and worse QoL [Ankylosing Spondylitis Quality of Life score difference 1.42 (95% CI 0.88, 1.96)] after adjusting for demographic, clinical and lifestyle factors. Among 291 participants who commenced biologic therapy, BASDAI scores in those with co-morbid FM were 2.0 higher at baseline but decreased to 1.1 higher at 12 months. There was no significant difference in the likelihood of meeting Assessment of SpondyloArthritis international Society 20 criteria at 12 months. Less improvement in disease activity and QoL over 3 months of TNFi therapy was most strongly related to high scores on the FM criteria symptom severity scale component.\ud Conclusion:\ud \ud Fulfilling criteria for FM has a modest impact on the assessment of axial SpA disease activity and QoL and does not significantly influence response to biologic therapy. Those with a high symptom severity scale on FM assessment may benefit from additional specific management for FM.

Published
2018

23. Influence of co-morbid fibromyalgia on disease activity measures and response to TNF inhibitors in axial spondyloarthritis : results from a UK national register

Author

Macfarlane, Gary J., MacDonald, Ross I. R., Pathan, Ejaz, Siebert, Stefan, Gaffney, Karl, Choy, Ernest, Packham, Jon, Martin, Kathryn R., Haywood, Kirstie L., Sengupta, Raj, Atzeni, Fabiola, and Jones, Gareth T.

Subjects
RC
Abstract

Objective \ud \ud To quantify the extent to which co-morbid fibromyalgia (FM) is associated with higher disease activity, worse quality of life and poorer response to TNF inhibition (TNFi) in patients with axSpa.\ud \ud Method\ud \ud A prospective study recruiting across 83 centres in the United Kingdom. Clinical information and patient reported measures were available, including 2011 criteria for FM. Multivariable linear regression was used to model the effect of meeting the FM criteria on disease activity, quality of life and response to TNFi.\ud \ud Results \ud \ud 1757 participants were eligible for analyses of whom 22.1% met criteria for FM. Those with comorbid FM criteria had higher disease activity (BASDAI average difference FM+ve - FM-ve 1.04; 95% CI 0.75, 1.33) and worse quality of life (ASQoL difference 1.42; 95% CI 0.88, 1.96) after adjusting for demographic, clinical and lifestyle factors. Amongst 291 participants who commenced biologic therapy, higher BASDAI scores in those with co-morbid FM reduced from 2.0 at baseline to 1.1 at 12 months and there was only a 3% difference (not significant) in likelihood of meeting ASAS20 criteria at 12 months. Less improvement in disease activity and quality of life over three months of TNFi therapy was most strongly related to high scores on the FM criteria symptom severity (SSS) component.\ud \ud Conclusion \ud \ud Fulfilling criteria for FM has a modest impact on assessment of axSpa disease activity and quality of life, and does not significantly influence response to biologic therapy. Those with high SSS on FM assessment, may benefit from specific management for FM.\ud

Published
2018

25. The co-occurrence and characteristics of patients with axial spondyloarthritis who meet criteria for fibromyalgia: results from a UK national register (BSRBR-AS)

Author

Macfarlane, Gary J., Barnish, Maxwell S., Pathan, Ejaz, Martin, Kathryn R., Haywood, Kirstie L., Siebert, Stefan, Packham, Jonathan, Atzeni, Fabiola, and Jones, Gareth T.

Abstract

Objective: To estimate the proportion of patients with axial spondyloarthritis (axSpA) who meet criteria for fibromyalgia (FM) and to characterise such patients.\ud \ud Methods: The British Society for Rheumatology Biologics Register of Ankylosing Spondylitis (BSRBR-AS) recruits two cohorts of patients who meet ASAS criteria for axSpA across 83 centres in the United Kingdom. Patients are either newly starting (biologic cohort) or naïve (non-biologic cohort) to biologic therapy and are followed prospectively. At recruitment and follow-up, clinical information and measurements are recorded, while patients complete the 2011 research criteria for FM, assessments of disease activity and impact.\ud \ud Results: 1504 patients (68% male) were eligible for the current analysis of whom 311 (20.7%) met criteria for FM. Prevalence was similar among those who fulfilled modified New York (mNY) criteria (19.7%), and ASAS imaging but not mNY criteria (25.2%), but lower among those who only fulfilled ASAS clinical criteria (9.5%). Patients who met FM criteria reported significantly worse disease activity, function, global severity scores, quality of life and were more likely to have moderate/severe levels of mood disorder and clinically important fatigue. They reported work impairment around half the time. Meeting FM criteria was not related to elevated C-reactive protein, or most extra-spinal manifestations, but was associated with a higher likelihood of having received biologic therapy.\ud \ud Conclusion: Developing management approaches that address the significant unmet needs of the 1 in 5 axSpA patients who meet criteria for FM should be a research priority.

Published
2017

28. Determining factors related to poor quality of life in patients with axial spondyloarthritis: results from the British Society for Rheumatology Biologics Register (BSRBR-AS).

Author

Macfarlane, Gary J., Rotariu, Ovidiu, Jones, Gareth T., Pathan, Ejaz, and Dean, Linda E.

Subjects
PAIN & psychology, RESEARCH, AFFECT (Psychology), PAIN, RHEUMATOLOGY, RESEARCH methodology, REGRESSION analysis, ACQUISITION of data, EVALUATION research, MEDICAL cooperation, SPONDYLOARTHROPATHIES, SEVERITY of illness index, FIBROMYALGIA, COMPARATIVE studies, QUALITY of life, MENTAL depression, FATIGUE (Physiology), LONGITUDINAL method, DISEASE complications
Abstract

Objective: To determine modifiable factors associated with poor quality of life (QoL) in patients with axial spondyloarthritis (axSpA).Methods: Analysis of data from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis (BSRBR-AS) and validation of a previous model using data from 1810 patients with axSpA recruited during 2012-2017. Data collected included clinical and patient-reported measures. QoL was assessed using the Ankylosing Spondylitis Quality of Life (ASQoL) measure. Linear regression models predicting ASQoL scores were used first to validate a previous model from a national study, to extend this with additional information available in BSRBR-AS and finally to identify a 'de novo' model from BSRBR-AS of which factors impact on poor QoL.Results: Four out of five factors included in a previous model of poor QoL in patients with axSpA were confirmed: Bath Ankylosing Spondylitis Disease Activity Index and Bath Ankylosing Spondylitis Functional Index, fatigue and widespread pain, although the performance of the model was improved by the addition of measures of mood and sleep disturbance. In a de novo model in BSRBR-AS, there were six factors (other than disease activity and function) that predicted ASQoL: depression (β=0.16), sleep disturbance (β=0.08), activity impairment (β=0.04), fibromyalgia (Symptom Severity Scale (β=0.24) and Widespread Pain Index (β=0.10)) and tobacco smoking (β=0.66).Conclusion: This study confirms that poor QoL in patients with axSpA, in addition to high disease activity and poor function, is independently influenced by sleep disturbance, mood and widespread pain. These additional factors are not considered targets for treatment in current European League Against Rheumatism (EULAR) guidelines for managing the condition. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

36. The British Society for Rheumatology Biologics Registers in Ankylosing Spondylitis (BSRBR-AS) study: Protocol for a prospective cohort study of the long-term safety and quality of life outcomes of biologic treatment

Author

Macfarlane, Gary J., primary, Barnish, Maxwell S., additional, Jones, Elizabeth A., additional, Kay, Lesley, additional, Keat, Andrew, additional, Meldrum, Karen T., additional, Pathan, Ejaz, additional, Sturrock, Roger D., additional, Zabke, Claudia, additional, McNamee, Paul, additional, and Jones, Gareth T., additional

Published
2015
Full Text
View/download PDF

39. The relationship between ankylosing spondylitis and periodontitis

Author

Abbood, Hadeel Mohammed, Cherukara, George, Pathan, Ejaz, and Macfarlane, Gary J.

Subjects
617.6, Periodontitis, Ankylosing spondylitis
Abstract

Periodontitis is a chronic inflammatory disease affecting the supporting tissue of the teeth. Previous studies showed that periodontitis has an aetiological association with other systemic diseases, such as cardiovascular diseases, diabetes mellitus and rheumatoid arthritis. Ankylosing spondylitis is a rheumatic disease affecting the axial skeleton and the sacroiliac joints. The concept of a link between ankylosing spondylitis and periodontitis was emerged around 14 years ago due to the common immunopathological picture between these two diseases. This dissertation aimed to investigate the association between ankylosing spondylitis and periodontitis. To save time and cost, self-reported questions were chosen to identify periodontitis. Results from a systematic review showed a high specificity and low sensitivity in using self-reported periodontitis. A series of studies were conducted using different databases to assess the link between these two diseases. The results showed increase in reporting oral health problems among ankylosing spondylitis compared to controls. An association between the presence of ankylosing spondylitis and reporting loose teeth and previous periodontal treatment was present. Increase ankylosing spondylitis disease activity was shown to be associated with reporting loose teeth. In conclusion, AS patients reported high prevalence of self-reported oral conditions relevant to periodontitis. However, the limitations present suggest further investigation.

Published
2019

40. Influence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis: results from a UK national register.

Author

Macfarlane GJ, MacDonald RIR, Pathan E, Siebert S, Gaffney K, Choy E, Packham J, Martin KR, Haywood K, Sengupta R, Atzeni F, and Jones GT

Subjects
Adult, Aged, Female, Humans, Male, Middle Aged, Registries, Severity of Illness Index, Spondylarthritis diagnosis, Spondylarthritis drug therapy, Treatment Outcome, United Nations, Antirheumatic Agents therapeutic use, Fibromyalgia complications, Spondylarthritis complications, Tumor Necrosis Factor-alpha antagonists & inhibitors
Abstract

Objective: To quantify the extent to which co-morbid FM is associated with higher disease activity, worse quality of life (QoL) and poorer response to TNF inhibitors (TNFis) in patients with axial SpA., Methods: A prospective study recruiting across 83 centres in the UK. Clinical information and patient-reported measures were available, including 2011 criteria for FM. Multivariable linear regression was used to model the effect of meeting the FM criteria on disease activity, QoL and response to TNFis., Results: A total of 1757 participants were eligible for analyses, of whom 22.1% met criteria for FM. Those with co-morbid FM criteria had higher disease activity [BASDAI average difference FM+ - FM- 1.04 (95% CI 0.75, 1.33)] and worse QoL [Ankylosing Spondylitis Quality of Life score difference 1.42 (95% CI 0.88, 1.96)] after adjusting for demographic, clinical and lifestyle factors. Among 291 participants who commenced biologic therapy, BASDAI scores in those with co-morbid FM were 2.0 higher at baseline but decreased to 1.1 higher at 12 months. There was no significant difference in the likelihood of meeting Assessment of SpondyloArthritis international Society 20 criteria at 12 months. Less improvement in disease activity and QoL over 3 months of TNFi therapy was most strongly related to high scores on the FM criteria symptom severity scale component., Conclusion: Fulfilling criteria for FM has a modest impact on the assessment of axial SpA disease activity and QoL and does not significantly influence response to biologic therapy. Those with a high symptom severity scale on FM assessment may benefit from additional specific management for FM.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results